Paclitaxel-loaded poly(n-butylcyanoacrylate) nanoparticle delivery system to overcome multidrug resistance in ovarian cancer

Pharmaceutical Research

Volumn 28, Issue 4, 2011, Pages 897-906

  Ren, Fei ^a   Chen, Ruda ^a   Wang, Ying ^a   Sun, Yabin ^a   Jiang, Yaodong ^a   Li, Guofeng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

multidrug resistance; nanoparticles; P glycoprotein function; P glycoprotein gene expression; paclitaxel

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CALCEIN; ENBUCRILATE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; NANOPARTICLE; PACLITAXEL; POLY(N BUTYLCYANOACRYLATE); UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NANOANALYSIS; NANOENCAPSULATION; NANOPHARMACEUTICS; OVARY CANCER; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENBUCRILATE; FEMALE; HUMANS; NANOPARTICLES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PARTICLE SIZE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOLUBILITY; SURFACE PROPERTIES;

EID: 79955620761     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0346-9     Document Type: Article

References (42)

1. BB Rogers 1993 Taxol: a promising new drug of the '90s Oncol Nurs Forum. 20 1483 9 7904060 1:STN:280:DyaK2c7gsFShtA%3D%3D
2. AK Singla A Garg D Aggarwal 2002 Paclitaxel and its formulations Int J Pharm. 235 179 92 11879753 10.1016/S0378-5173(01)00986-3 1:CAS:528: DC%2BD38XhsV2qsro%3D (Pubitemid 34185449)
3. RT Liggins WL Hunter HM Burt 1997 Solid-state characterization of paclitaxel J Pharm Sci. 86 1458 63 9423162 10.1021/js9605226 1:CAS:528:DyaK2sXnsFSitrs%3D (Pubitemid 28018330)
4. H Gelderblom J Verweij K Nooter A Sparreboom EL Cremophor 2001 The drawbacks and advantages of vehicle selection for drug formulation Eur J Cancer 37 1590 8 11527683 10.1016/S0959-8049(01)00171-X 1:CAS:528:DC%2BD3MXmt1Oqtb0%3D (Pubitemid 32778603)
5. RZ Yusuf Z Duan DE Lamendola RT Penson MV Seiden 2003 Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation Curr Cancer Drug Targets 3 1 1 19 12570657 10.2174/1568009033333754 1:CAS:528: DC%2BD3sXlsVGntg%3D%3D (Pubitemid 36119417)
6. SK Calderwood MA Khaleque DB Sawyer DR Ciocca 2006 Heat shock proteins in cancer: chaperones of tumorigenesis Trends Biochem Sci. 31 164 72 16483782 10.1016/j.tibs.2006.01.006 1:CAS:528:DC%2BD28Xit1ymsL4%3D (Pubitemid 43361923)
7. V Kirkin S Joos M Zörnig 2004 The role of Bcl-2 family members in tumorigenesis Biochim Biophys Acta. 1644 229 49 14996506 10.1016/j.bbamcr.2003. 08.009 1:CAS:528:DC%2BD2cXhslWnsrk%3D (Pubitemid 38281277)
8. G Szakács JK Paterson JA Ludwig C Booth-Genthe MM Gottesman 2006 Targeting multidrug resistance in cancer Nat Rev Drug Discov. 5 219 34 16518375 10.1038/nrd1984 (Pubitemid 43336035)
9. R O'Connor 2007 The pharmacology of cancer resistance Anticancer Res. 27 1267 72 17593618 (Pubitemid 46813088)
10. WD Stein SE Bates T Fojo 2004 Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack Curr Drug Targets. 5 333 46 15134216 10.2174/1389450043345489 1:CAS:528:DC%2BD2cXjs1GnsLo%3D (Pubitemid 38559343)
11. C Cuvier L Roblot-Treupel JM Millot G Lizard S Chevillard M Manfait P Couvreur MF Poupon 1992 Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance Biochem Pharmacol. 44 509 17 1354963 10.1016/0006-2952(92) 90443-M 1:CAS:528:DyaK38XlvFygs74%3D
12. CE Soma C Dubernet G Barratt F Némati M Appel S Benita P Couvreur 1999 Ability of doxorubicin-loaded nanoparticles to overcome multi-drug resistance of tumor cells after their capture by macrophages Pharm Res 16 1710 6 10571276 10.1023/A:1018902031370 1:CAS:528:DyaK1MXnt1Ggs7Y%3D (Pubitemid 29530403)
13. H Önyüksel E Jeon I Rubinstein 2009 Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells Cancer Letters 274 327 30 19022562 10.1016/j.canlet.2008.09.041
14. T Minko P Kopeckova V Pozharov J Kopecek 1998 HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line J Control Release 54 223 33 9724909 10.1016/S0168-3659(98)00009-1 1:CAS:528:DyaK1cXksVWnt7Y%3D (Pubitemid 28342701)
15. CY Huang CM Chen YD Lee 2007 Synthesis of high loading and encapsulation efficient paclitaxel-loaded poly(n-butyl cyanoacrylate) nanoparticles via miniemulsion Int J Pharm. 338 267 75 17368981 10.1016/j.ijpharm.2007.01.052 1:CAS:528:DC%2BD2sXlslWgsrk%3D (Pubitemid 46777229)
16. P Couvreur B Kante V Lenaerts V Scailteur M Roland P Speiser 1980 Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles J Pharm Sci. 69 199 202 7359324 10.1002/jps.2600690222 1:CAS:528:DyaL3cXitVylu7k%3D (Pubitemid 10096549)
17. P Couvreur E Fattal H Alphandary F Puisieux A Andremont 1992 Intracellular targeting of antibiotics by means of biodegradable nanoparticles J Control Release 19 259 67 10.1016/0168-3659(92)90081-2 1:CAS:528: DyaK38Xit1Wnsbs%3D
18. C Damge C Michel M Aprahamian P Couvreur JP Devissaguet 1990 Nanocapsules as carriers for oral peptide delivery J Control Release 13 233 39 10.1016/0168-3659(90)90013-J 1:CAS:528:DyaK3cXmtlOktr4%3D (Pubitemid 20313521)
19. Ch Tasset N Barette S Thysman JM Ketelslegers D Lemoine V Preat 1995 Polyisobutylcyanoacrylate nanoparticles as sustained release system for calcitonin J Control Release 33 23 30 10.1016/0168-3659(94)00060-8 1:CAS:528:DyaK2MXjt1Srt7o%3D
20. Y Li M Ogris E Wagner J Pelisek M Rüffer 2003 Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation Int J Pharm. 259 93 101 12787639 10.1016/S0378-5173(03)00211-4 1:CAS:528:DC%2BD3sXktF2rtrc%3D (Pubitemid 36638557)
21. F Némati C Dubernet AC de Verdière MF Pouponb L Treupel-Acarc F Puisieux P Couvreur 1994 Some parameters influencing cytotoxicity of free doxorubicin and doxorubiicn-loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells: incubation time, number of nanoparticles per cell Int J Pharm 102 55 62 10.1016/0378-5173(94)90039-6 (Pubitemid 124013789)
22. AC de Verdière C Dubernet F Némati E Soma M Appel J Ferté S Bernard F Puisieux P Couvreur 1997 Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action Br J Cancer. 76 198 205 9231919 10.1038/bjc.1997.362 (Pubitemid 27279659)
23. X Dong CA Mattingly MT Tseng MJ Cho Y Liu VR Adams RJ Mumper 2009 Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP Cancer Res. 69 3918 26 19383919 10.1158/0008-5472.CAN-08-2747 1:CAS:528:DC%2BD1MXltFOksb4%3D
24. Y Zhang L Tang L Sun J Bao C Song L Huang K Liu Y Tian G Tian Z Li H Sun L Mei 2010 A novel paclitaxel-loaded poly(epsilon-caprolactone)/Poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment Acta Biomater. 6 2045 52 19969111 10.1016/j.actbio.2009.11.035 1:CAS:528: DC%2BC3cXnsVOlurY%3D
25. J Ravindran HB Nair B Sung S Prasad RR Tekmal BB Aggarwal 2010 Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential Biochem Pharmacol. 79 1640 7 20105430 10.1016/j.bcp.2010.01.023 1:CAS:528: DC%2BC3cXjvFKmt7o%3D
26. HL Wong AM Rauth R Bendayan JL Manias M Ramaswamy Z Liu SZ Erhan XY Wu 2006 A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells Pharm Res 23 1574 85 16786442 10.1007/s11095-006-0282-x 1:CAS:528:DC%2BD28XmsFOmu7o%3D (Pubitemid 43993820)
27. HL Wong R Bendayan AM Rauth HY Xue K Babakhanian XY Wu 2006 A mechanistic study of enhanced doxorubicin uptake and retention in multi-drug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system J Pharmacol Exp Ther. 317 1372 81 16547167 10.1124/jpet.106.101154 1:CAS:528: DC%2BD28Xlt1equ78%3D (Pubitemid 43764144)
28. MD Chavanpatil Y Patil J Panyam 2006 Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux Int J Pharm 320 150 6 16713148 10.1016/j.ijpharm.2006.03.045 1:CAS:528: DC%2BD28XnsFCqtb4%3D (Pubitemid 44128700)
29. T Hekmatara S Gelperina V Vogel SR Yang J Kreuter 2009 Encapsulation of water-insoluble drugs in poly(butyl cyanoacrylate) nanoparticles J Nanosci Nanotechnol. 9 5091 8 19928187 10.1166/jnn.2009.GR05 1:CAS:528: DC%2BD1MXht1yrsbfP
30. JW Polli SA Wring JE Humphreys L Huang JB Morgan LO Webster CS Serabjit-Singh 2001 Rational use of in vitro P-glycoprotein assays in drug discovery J Pharmacol Exp Ther. 299 620 8 11602674 1:CAS:528: DC%2BD3MXnvV2qt78%3D (Pubitemid 32979675)
31. M Susa AK Iyer K Ryu FJ Hornicek H Mankin MM Amiji Z Duan 2009 Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma BMC Cancer. 9 399 19917123 10.1186/1471-2407-9-399
32. A Mitra S Lin 2003 Effect of surfactant on fabrication and characterization of paclitaxel-loaded polybutylcyanoacrylate nanoparticulate delivery systems J Pharm Pharmacol. 55 895 902 12906746 10.1211/0022357021341 1:CAS:528:DC%2BD3sXmsVaisLc%3D (Pubitemid 36916679)
33. L Mu SS Feng 2001 Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers J Control Release. 76 239 54 11578739 10.1016/S0168-3659(01)00440-0 1:CAS:528:DC%2BD3MXntVWksbw%3D (Pubitemid 32913433)
34. WJ Slichenmyer DD Von Hoff 1991 Taxol: a new and effective anti-cancer drug Anticancer Drugs. 2 519 30 1687206 10.1097/00001813-199112000-00002 1:CAS:528:DyaK38XhvVOgtr4%3D
35. SK Dordunoo HM Burt 1996 Solubility and stability of taxol: effects of buffers and cyclodextrins Int J Pharm 133 191 201 10.1016/0378-5173(96)04443-2 1:CAS:528:DyaK28Xjt1Sntbw%3D (Pubitemid 26163334)
36. M He Z Zhao L Yin C Tang C Yin 2009 Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers Int J Pharm. 373 165 73 19429302 10.1016/j.ijpharm.2009.02.012 1:CAS:528:DC%2BD1MXltlSjtrw%3D
37. I Brigger C Dubernet P Couvreur 2002 Nanoparticles in cancer therapy and diagnosis Adv Drug Deliv Rev 54 5 631 51 12204596 10.1016/S0169-409X(02)00044-3 1:CAS:528:DC%2BD38XmsVeqtrs%3D (Pubitemid 35247520)
38. AK Larsen AE Escargueil A Skladanowski 2000 Resistance mechanisms associated with altered intracellular distribution of anticancer agents Pharmacol Ther. 85 3 217 29 10739876 10.1016/S0163-7258(99)00073-X 1:CAS:528:DC%2BD3cXitVWjs7Y%3D (Pubitemid 30160791)
39. K Bogman F Erne-Brand J Alsenz J Drewe 2003 The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins J Pharm Sci. 92 1250 61 12761814 10.1002/jps.10395 1:CAS:528:DC%2BD3sXks1Kisb8%3D (Pubitemid 36676470)
40. YL Lo 2000 Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats Biochem Pharmacol. 60 1381 90 11008132 10.1016/S0006-2952(00)00451-2 1:CAS:528:DC%2BD3cXmslOjtL0%3D
41. B Bauer DS Miller G Fricker 2003 Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system Pharm Res. 20 1170 6 12948014 10.1023/A:1025040712857 1:CAS:528:DC%2BD3sXmtVGrtLo%3D (Pubitemid 36951841)
42. Y Mitsunaga H Takanaga H Matsuo M Naito T Tsuruo H Ohtani Y Sawada 2000 Effect of bioflavonoids on vincristine transport across blood-brain barrier Eur J Pharmacol. 395 193 201 10812049 10.1016/S0014-2999(00)00180-1 1:CAS:528:DC%2BD3cXjt1eitb0%3D (Pubitemid 30254368)